Where does Delta-Fly Pharma, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Delta-Fly Pharma, Inc. ranks #26,113 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Delta-Fly Pharma, Inc. hold?

Delta-Fly Pharma, Inc. holds 10 US utility patents granted between 2017 and 2024, spanning 12 technology areas.

What is Delta-Fly Pharma, Inc.'s Innovation Score?

Delta-Fly Pharma, Inc. has an Innovation Score of 43.3 out of 100 (top 28% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Delta-Fly Pharma, Inc. focus on?

Delta-Fly Pharma, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 10 patents, ranking #1,884 of 6,058 assignees active in that subclass. Grants appear in 12 CPC subclasses total.

Is Delta-Fly Pharma, Inc.'s patent grant rate increasing or decreasing?

Delta-Fly Pharma, Inc.'s recent grant velocity is +50% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Delta-Fly Pharma, Inc.'s patents?

Delta-Fly Pharma, Inc.'s patents average 10.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Delta-Fly Pharma, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Delta-Fly Pharma, Inc.

USPTO PatentsView assignee record - 10 granted patents across 12 technology areas, recorded in grant years 2017–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Delta-fly ranks #26,113 of 49,997 tracked US assignees by granted-patent volume, with 10 patents across 12 technology areas.

#26,113
of 49,997 US assignees by volume: Top 28%
by Innovation Score (43.3/100): 10.2
avg claims per patent: +50%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R26113 · Foreign Corporation #26,113 · 10 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-PAR · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 10 grants
MID-PACK #26,113/49,997
PHOTO-FINISH Datorama
CPC-FOCUS A61P · 12 areas
INNOV-PAR 43.3/100
CLAIMS-PAR 10.2 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +50% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Datorama Technologies Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Delta-fly’s 43.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.3 pts (19%) Velocity 16.7 pts (39%) Breadth 12.2 pts (28%) Claim depth 6.1 pts (14%)

Qualcomm Incorporated · highest

85
Delta-Fly Pharma · this assignee

43
3D Lighting… · lowest

7

What this shows Delta-fly's Innovation Score is 43.3/100 (top 28% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Delta-fly?

Each dot is one of Delta-fly’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Delta-fly’s own 10.2 claims/patent is at or below the 16.9 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Delta-fly vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Delta-fly's grants concentrate

Delta-Fly Pharma, Inc. is a focused PatentsView assignee: 12 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2018 (2 grants) versus a trough of 1 in 2017. By volume, Delta-fly sits between Datorama Technologies Ltd. and Diamanti, Inc..

Delta-fly's three-year grant acceleration

Delta-Fly Pharma, Inc. shows 5 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Datorama

10
Daymen US

10
Decibel Therapeut…

10
Defender Screens…

10
Design Blue

10
Destiny Software…

10
Devicefidelity

10
Diamanti

10
Delta-fly Pharma ◀

10

What this shows Delta-Fly holds 10 patents at rank #26,144, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Delta-Fly

By rank, the assignees closest to #26,144 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Delta-Fly's primary technology class.

Delta-fly's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

43 Top 28% higher than 72% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Delta-Fly Pharma, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	10.0%
2018	2	20.0%
2019	1	10.0%
2021	1	10.0%
2022	2	20.0%
2023	2	20.0%
2024	1	10.0%

Which technologies does Delta-Fly Pharma, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 10

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 10

C07K - Peptides 2

C08G - Macromolecular Compounds Obtained Otherwise Than BY Reactions Only Involving Unsaturated Carbon-to-carbon Bonds 2

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 2

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 1

A61B - DIAGNOSIS; SURGERY; Identification 1

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

G01R - Measuring Electric VARIABLES; Measuring Magnetic Variables 1

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 1

C07D - Heterocyclic Compounds 1

A23L - Foods, Foodstuffs OR Non-alcoholic Beverages, NOT Otherwise Provided FOR; Preparation OR Treatment Thereof 1

Top 12 of 12 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Delta-Fly Pharma, Inc.'s patent record in context - here's where to go next.

Delta-Fly Pharma, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #26,113 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Delta-Fly Pharma, Inc. against Datorama Technologies Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 43.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.